SRPT · Sarepta Therapeutics, Inc.

$18.10 -0.32 (-1.74%) At close · Aug 14

Market Cap

$1.91B

105.63M

Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.

Program Authorized

$500,000,000

as of 2024-11-01 · from 10-Q (reviewed)

Remaining Authorization

$475,000,000

as of 2025-12-31

Program Utilization

5.0% $25,000,000 used of $500,000,000

Program Announced	Authorized	Remaining	As of	Runs Through	Source
2024-11-01	$500,000,000	—	—	—	10-Q , filed 2026-08-05

Repurchase History

Fiscal Year Ended	Cash Spent	Shares	Avg Price	Source
2025-12-31	$25,013,000	—	—	10-K, filed 2026-03-02

2024-12-31	$0	—	—	10-K, filed 2026-03-02
2023-12-31	$0	—	—	10-K, filed 2026-03-02

Quarter Ended	Cash Spent	Shares	Avg Price	Source
2025-12-31	$0 Δ	—	—	10-K, filed 2026-03-02
2025-09-30	$0 Δ	—	—	10-Q, filed 2025-11-06
2024-12-31	$0 Δ	—	—	10-K, filed 2026-03-02
2024-09-30	$0 Δ	—	—	10-Q, filed 2025-11-06
2012-09-30	$0 Δ	—	—	10-Q, filed 2012-11-07
2012-06-30	$0 Δ	—	—	10-Q, filed 2012-08-07
2012-03-31	$0	—	—	10-Q, filed 2012-05-10
2011-09-30	$0 Δ	—	—	10-Q, filed 2012-11-07
2011-06-30	$0 Δ	—	—	10-Q, filed 2012-08-07
2011-03-31	$0	—	—	10-Q, filed 2012-05-10

Key facts CIK 873303 CUSIP 803607100 13F (30d) 333 filings 300 filers Visit website Investor relations